Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.
The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.
Congress Report ESMO 2017
Highlights include the latest clinical trial results for the PD-L1 inhibitors atezolizumab and durvalumab, new data for the PD-1 inhibitor nivolumab and the toll-like receptor 9 agonist lefitolimod; a discussion of the optimal succession of targeted agents across several treatment lines for both EGFR and ALK positive disease; positive data for combined dabrafenib/trametinib therapy for BRAF-positive lung cancer patients; and lots more besides.
Medical education Fundamentals of designing clinical trials: Part 2: Contemporary designs of phase I and II trials in oncology including endpoint selection and quality of life as an endpoint
Sensible endpoint selection design is a critical part of oncological clinical trial design, and is explored here. This issue looks at the usage of QOL as an endpoint, and discusses the critical aspects of…READ MORE
Expert interviews at ESMO
Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.
Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.
Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.
Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.